Benitec Biopharma Limited is an Australia-based company engaged in developing treatments for chronic and life-threatening conditions based on a transformational technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid (RNA) interference (ddRNAi). The Company�s therapeutic programs include human immunodeficiency virus (HIV), Hepatitis B, oculopharyngeal muscular dystrophy (OPMD) orphan disease, delivery options and cancer. The Company operates in global commercialization by licensing and partnering of patents and licenses in biotechnology, more specifically in functional genomics, with applications in biomedical research and human therapeutics. During the fiscal year ended June 30, 2012, the Company�s wholly owned subsidiaries include Benitec Australia Limited, Benitec Biopharma Limited, Benitec, Inc., Benitec LLC and RNAi Therapeutics, Inc. In October 2012, the Company acquired Tacere Therapeutics, Inc.